Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

by admin | Dec 23, 2022 | Press Release

Program builds on Lumen’s leading position in the development of complex biologic drug cocktails Seattle, WA, December 23, 2022 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the...

BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study

by admin | Dec 20, 2022 | Press Release

Administration of LMN-301 pre- and post-viral challenge associated with improved clinical outcomes Seattle, WA, December 20, 2022 – Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today...

Lumen’s AI Analysis Frees Production Optimization from DOE Limits

by admin | Dec 7, 2022 | Press Release

Read more

On the Horizon, Needle-Free Vaccines could Offer Better Protection and Access

by admin | Oct 25, 2022 | Press Release

Read more

Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria

by admin | Oct 4, 2022 | Press Release

Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research,...

Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test

by admin | Oct 4, 2022 | Press Release

Read more